GXE:ETR
Lakefront Biotherapeutics NV
€26,28
arrow_downward
-0,83%(-0,22) 1D
13 ຕ.ລ., 17 ໂມງ 35 ນາທີ 58 ວິນາທີ GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GXE...
Open
€26,40
High
€26,46
Low
€26,22
Mkt. cap
1,73 ຕື້
Avg. vol.
523,00
Volume
913,00
P/E ratio
2,90
52-wk high
€30,02
52-wk low
€22,84
EPS
€9,05
No. of employees
196
Open
€26,40
High
€26,46
Low
€26,22
Mkt. cap
1,73 ຕື້
Avg. vol.
523,00
Volume
913,00
P/E ratio
2,90
52-wk high
€30,02
52-wk low
€22,84
EPS
€9,05
No. of employees
196
News stories
From web sources and news partners
Yahoo Finance
·
29 ນາທີກ່ອນ
Stock Market: Will S&P 500 Open Up or Down Today?
Seeking Alpha
·
14 ນາທີກ່ອນ
It Might Not Be Over Soon: A Decade Of Explosive Growth In The Options Market
Stocktwits
·
33 ນາທີກ່ອນ
UNH Stock Outpaces S&P 500 In 2026, Eyes Best Year Since Pandemic — CFO Says Wall Street May Be Missing 2027 Upside
The Motley Fool
·
1 ຊົ່ວໂມງກ່ອນ
The S&P 500 Just Hit a Record High. Here's Why History Says It's Still a Smart Time to Invest.
Profile
Lakefront Biotherapeutics is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.
The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis. Wikipedia
About Lakefront Biotherapeutics NV
CEOPaul Stoffels | Paul Stoffels
Employees196
Founded1999
Headquarters-
SectorBiotechnology
Websitelakefrontbio.com